U.S. Markets closed
  • S&P Futures

    4,533.25
    -42.50 (-0.93%)
     
  • Dow Futures

    34,559.00
    -63.00 (-0.18%)
     
  • Nasdaq Futures

    15,687.50
    -301.00 (-1.88%)
     
  • Russell 2000 Futures

    2,156.20
    -49.00 (-2.22%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.57
    +0.25 (+1.12%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.1019%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    30.67
    +2.72 (+9.73%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.5029%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.3613%)
     
  • BTC-USD

    51,186.23
    +1,939.54 (+3.94%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

NERV ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 8, 2021 in the Class Action Filed on Behalf of Minerva Neurosciences, Inc. Limited Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - January 21, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NASDAQ: NERV) alleging that the Company violated federal securities laws.

Class Period: May 15, 2017 and November 30, 2020
Lead Plaintiff Deadline: February 8, 2021

Learn more about your recoverable losses in NERV:
http://www.kleinstocklaw.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?id=12333&from=5

The filed complaint alleges that Minerva Neurosciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the "end-of-Phase 2" meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be "highly unlikely" to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to "substantial review issues" because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders have until February 8, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the NERV lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72543